GET DAILY SIGNALSQuest Diagnostics (DGX) vs Labcorp (LH): Comparing Momentum in the Diagnostics Sector
Key Takeaways
- Quest Diagnostics and Labcorp are the two largest independent clinical laboratories in the United States, making this a direct comparison of market leaders within the same diagnostics sector.
- DGX is delivering faster organic test-volume growth and higher operating margins, while LH commands a larger revenue base and a more diversified business model.
- Both companies posted beat-and-raise quarters in recent weeks, but LH shares responded with stronger positive momentum and a wave of analyst price-target increases.
- Tickeron AI Verdict: Labcorp (LH) — based on relative momentum, catalysts, and market positioning, the AI framework currently favors LH over DGX.
- Explore deeper coverage of each ticker through their respective major news and price move updates.
- Discover the best-performing AI trading strategies for today's market in the Trending AI Robots section.
Introduction
Quest Diagnostics (DGX) and Labcorp Holdings (LH) sit at the center of the U.S. diagnostics and laboratory-testing industry, competing for the same physician, hospital, and consumer testing demand. Because these two companies operate in nearly identical end markets yet pursue different growth strategies, a side-by-side stock comparison offers investors a useful lens on sector-level momentum, margin quality, and valuation trade-offs. This analysis is most relevant to investors and traders evaluating healthcare-services exposure, those weighing defensive growth names, and anyone seeking a data-driven view of which of the two leaders currently presents the more favorable market positioning.
Quest Diagnostics (DGX) Overview and Recent Performance
Quest Diagnostics (DGX) is a leading independent provider of diagnostic testing and information services, operating a national network of roughly 2,400 patient service centers alongside physician offices and hospitals. The company generates nearly all of its revenue from clinical testing, advanced diagnostics, and wellness offerings such as its QuestHealth.com consumer platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent market activity has highlighted strong fundamental momentum. In its latest quarterly report, Quest delivered roughly 10% revenue growth and adjusted earnings per share (EPS) growth above 15%, marking another beat-and-raise quarter. Organic requisition volume — the number of tests performed — climbed at a double-digit rate, reinforcing demand across physician, hospital, and consumer channels. Even so, the stock's post-earnings reaction was comparatively muted, with shares trading modestly higher over recent weeks. Analysts have noted solid relative strength and a strong composite rating, though reimbursement uncertainty tied to the Protecting Access to Medicare Act (PAMA) and elevated debt levels remain key watch items.
Labcorp (LH) Overview and Recent Performance
Labcorp Holdings (LH) is one of the two largest independent clinical laboratories in the nation, holding an estimated 20% share of the independent lab market. Its business spans two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS), the latter supporting drug development from early research through clinical trials. From what I see, this diversification stands out when comparing the two names.
In recent weeks, Labcorp has displayed notable momentum. Its latest quarterly results showed revenue growth of roughly 7% and adjusted EPS growth near 15%, with both segments contributing and the company raising its full-year outlook. Shares advanced sharply following the report, and a succession of analysts raised price targets, reflecting confidence in specialty-testing growth, acquisitions, and margin expansion. Labcorp has been active in mergers and acquisitions, adding specialty and prenatal testing assets. Like its peer, Labcorp faces potential PAMA reimbursement headwinds, but its diversified biopharma segment and favorable pricing mix have supported investor sentiment.
Head-to-Head Comparison
The two companies diverge in several meaningful ways. Quest Diagnostics is more concentrated, deriving the overwhelming majority of revenue from routine and advanced clinical testing, which gives it faster organic volume growth and a higher adjusted operating margin. Labcorp, by contrast, layers a fast-growing Biopharma Laboratory Services business on top of its diagnostics segment, providing revenue diversification and exposure to pharmaceutical and biotech research spending.
On growth drivers, DGX leans on advanced diagnostics — including its AD-Detect Alzheimer's portfolio and Haystack minimal residual disease (MRD) oncology testing — plus automation and AI-driven efficiency. LH emphasizes specialty testing in oncology, neurology, autoimmune, and women's health, reinforced by an active acquisition strategy. On recent momentum, LH's shares reacted more decisively to earnings and attracted multiple analyst upgrades, while DGX's advance has been steadier but less dramatic. Risk factors overlap considerably, including PAMA reimbursement pressure and balance-sheet leverage, though LH's diversified revenue and BLS order book provide an additional cushion against testing-volume swings.
Tickeron AI Verdict
Based on observable factors — trend consistency, stability, catalysts, and relative positioning — Tickeron's AI framework currently favors Labcorp (LH) over Quest Diagnostics (DGX). LH's sharper positive price reaction to a beat-and-raise quarter, its wave of analyst upgrades, and its more diversified two-segment model contribute to a comparatively stronger momentum profile. DGX remains a high-quality operator with superior organic volume growth and margin quality, so the preference is probabilistic rather than absolute. Both names warrant monitoring, but on the current setup, the AI-weighted balance of catalysts and relative strength tilts toward Labcorp. I also checked this using Tickeron’s AI Trend Prediction Engine for additional context on the relative positioning.
Exploring Trending AI Robots for Strategy Ideas
In my own research process, I sometimes review Tickeron’s Trending AI Robots to see which strategies are gaining traction in the current environment. This section highlights bots suited to prevailing conditions across different styles, timeframes, and ticker sets, helping align approaches with individual risk preferences when evaluating names like these.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
LH's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for LH turned positive on October 08, 2026. Looking at past instances where LH's MACD turned positive, the stock continued to rise in 34 of 51 cases over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on LH as a result. In 59 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
LH moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LH crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +11.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where LH advanced for three days, in 191 of 333 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 117 of 206 cases where LH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
LH broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. LH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.454) is normal, around the industry mean (65.710). P/E Ratio (30.121) is within average values for comparable stocks, (4.185). Projected Growth (PEG Ratio) (1.206) is also within normal values, averaging (3.473). LH has a moderately high Dividend Yield (0.008) as compared to the industry average of (0.002). P/S Ratio (1.876) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Can I Establish a Keogh Plan?
What are Bond Ratings?
Tickeron Launches Token on Believe App to Engage Crypto Community and Expand Reach
S&P 500, Meet Your Match: Tickeron's Robot Leads the Way to Market Success!
Top 10 AI Trading Agents: New Tickeron Bot Hits strong performance for Retail Investors (SATS)
General Information
a provider of medical testing services
Industry MedicalSpecialties
Advertisement